Day: October 21, 2023

Notice for a bondholder meeting

Written by Customer Service on . Posted in Public Companies.

MILA 300929 – Bondholders meeting 20 October 2023 In accordance with the provisions of the bond MILA 300929 (the “Bond”), Sunstone IV hf. (the “Issuer”) now calls for a Bondholders Meeting, to be held at the Issuer’s office at Stórhöfði 22-30, 110 Reykjavík, Iceland at 13:00 on 6 November 2023. The Bondholders Meeting’s agenda: Proposal to change the Article of the Bond relating to payments of principal and interest, for the purpose of correcting a drafting error in the Bond. Attached to this meeting notification are the Issuer’s proposals. In accordance with the provisions of the Bond, the Bond can be amended by a Bondholders Meeting, which shall be called with no less than two-week notice. Bondholders Meetings can conclude all matters within the agenda if the meeting is called in accordance with the provisions of the Bond. The voting...

Continue reading

Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023

Written by Customer Service on . Posted in Public Companies.

Confirmed response rate 35% (11/31), across all tumor types and patient cohorts treated with 1 mg priming dose, including three confirmed, complete responses 32% (6/19) confirmed response rate in patients with small cell lung cancer (SCLC), including one confirmed complete response 42% (5/12) confirmed response rate in other neuroendocrine tumor types, including two confirmed complete responses Generally well tolerated; cytokine release syndrome (CRS) most common, predominantly low-grade, with no Gr3 CRS in 1 mg priming dose cohorts Enrollment in monotherapy dose cohorts nearing completion, on track to select Phase 2 dose(s) by end of 2023 Results will be presented in a poster session at ESMO Congress 2023 on Monday, October 23, 2023 and management will hold a webcast at 8:00 a.m. ET / 2:00 p.m. CEST to review the data, following...

Continue reading

Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)

Written by Customer Service on . Posted in Public Companies.

89% estimated event-free survival at one year among patients with stage II to IV resectable CSCC who received Libtayo prior to surgery in a Phase 2 trial No disease recurrence among the 51% of patients who experienced a pathologic complete response in the primary analysis TARRYTOWN, N.Y., Oct. 21, 2023 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentation of key secondary endpoints for an investigational regimen of PD-1 inhibitor Libtayo® (cemiplimab) as a neoadjuvant monotherapy in stage II to IV resectable cutaneous squamous cell carcinoma (CSCC). The results from an international Phase 2 trial were presented in an oral session at the European Society for Medical Oncology (ESMO) Congress 2023 and concurrently published in The Lancet Oncology. “Advanced, resectable cutaneous...

Continue reading

Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial

Written by Customer Service on . Posted in Public Companies.

Data published in New England Journal of Medicine and presented as a late breaking abstract in mini oral session at ESMO Congress 2023 KIMMTRAK demonstrated long-term survival benefit in HLA-A*02:01 positive patients with previously untreated metastatic uveal melanoma (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 21 October 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, today announces that the three-year overall survival (OS) data from the KIMMTRAK (tebentafusp-tebn) Phase 3 trial in previously untreated HLA-A*02:01 positive patients with metastatic uveal melanoma has...

Continue reading

Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile

Written by Customer Service on . Posted in Public Companies.

CNS activity observed at multiple dose levels, including the first reported confirmed CNS complete response by an EGFR exon 20 inhibitor in a patient with documented untreated brain metastases Systemic responses observed at multiple dose levels in heavily pre-treated NSCLC patients, characterized by 81% having received prior EGFR exon 20 targeted agents and 86% having CNS metastases at baseline At potential RP2D of 75 mg QD, responses observed in 2 of 3 EGFR exon 20 patients previously treated with amivantamab (67% ORR), including a confirmed complete response Responses observed at multiple dose levels in HER2 exon 20 patients, including a partial response with 100% target lesion regression Favorable safety profile with mainly Grade 1 and 2 treatment related adverse events; MTD not reached and dose escalation remains ongoing Company...

Continue reading

Vortex Energy Announces Extension of Marketing Program

Written by Customer Service on . Posted in Public Companies.

VANCOUVER, British Columbia, Oct. 20, 2023 (GLOBE NEWSWIRE) — Vortex Energy Corp. (CSE: VRTX | OTC: VTECF | FRA: AA3) (“Vortex” or the “Company“) is pleased to announce, further to its news releases on April 28, 2023, June 23, 2023, July 21, 2023, and September 1st, 2023, that it has further extended its engagement of Financial Star News Inc. (“FSN”) (address: 701 West Georgia Street, Suite 1500, Vancouver, British Columbia V7Y 1C6; email: info@thefinancialstar.com) for marketing services for up to an additional 45 days commencing on October 23rd, 2023, provided that the term of the marketing services may be extended or shortened at the discretion of management depending on, amongst other things, the efficiency of the marketing services. As previously disclosed, FSN has and shall continue to, as appropriate, create...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.